Hem › Hypofarynxcancer › Michigan
Kliniska studier för Hypofarynxcancer i Michigan
5 studier för Hypofarynxcancer söker deltagare vid platser i Michigan.
Städer i Michigan
- Lansing4 studier
- Flint4 studier
- Waterford4 studier
- Ann Arbor3 studier
- Detroit3 studier
- Livonia3 studier
- Canton3 studier
Officiell studietext (engelska)
Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment
- Trinity Health Saint Joseph Mercy Hospital Ann Arbor, Ann Arbor
- Trinity Health IHA Medical Group Hematology Oncology - Brighton, Brighton
- Trinity Health IHA Medical Group Hematology Oncology - Canton, Canton
- och 8 fler
RekryterarFas 3
Ålder 18 och äldre · Alla kön · Uppdaterad 1 okt. 2026 · NCT06589804BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study
- Trinity Health Saint Joseph Mercy Hospital Ann Arbor, Ann Arbor
- University of Michigan Rogel Cancer Center, Ann Arbor
- Bronson Battle Creek, Battle Creek
- och 23 fler
RekryterarFas 2
Ålder 18 och äldre · Alla kön · Uppdaterad 25 sep. 2026 · NCT05136196Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery
- MyMichigan Medical Center Gratiot, Alma
- MyMichigan Medical Center Alpena, Alpena
- Trinity Health Saint Joseph Mercy Hospital Ann Arbor, Ann Arbor
- och 60 fler
RekryterarFas 2
Ålder 18 och äldre · Alla kön · Uppdaterad 14 sep. 2026 · NCT02734537Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer
- McLaren Cancer Institute-Bay City, Bay City
- McLaren Cancer Institute-Clarkston, Clarkston
- Wayne State University/Karmanos Cancer Institute, Detroit
- och 8 fler
RekryterarFas 2
Ålder 18 och äldre · Alla kön · Uppdaterad 17 aug. 2026 · NCT06532279Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
- Henry Ford Cancer Institute, Detroit
RekryterarFas 1/2
Ålder 18 och äldre · Alla kön · Uppdaterad 29 juli 2026 · NCT04198766Från ClinicalTrials.gov, data hämtad 6 okt. 2026. Varje studie har egna kvalifikationskrav; studieteamet avgör vem som kan delta.